Leukemia  >>  Phase 1
Welcome,         Profile    Billing    Logout  

841 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leukemia
NCI-2021-09185, NCT05157971: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

Recruiting
1
6
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Mercaptopurine, 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, Bw 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Pegaspargase, L-Asparaginase with Polyethylene Glycol, Oncaspar, Oncaspar-IV, PEG-Asparaginase, PEG-L-Asparaginase, PEG-L-Asparaginase (Enzon - Kyowa Hakko), PEGLA, Polyethylene Glycol L-Asparaginase, Polyethylene Glycol-L-Asparaginase, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
City of Hope Medical Center, National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia
05/24
05/24
GLB-001-02, NCT06378437: A Study of GLB-001 in Patients With Myeloid Malignancies

Recruiting
1
108
RoW
GLB-001, GLB-C183-A-2
Hangzhou GluBio Pharmaceutical Co., Ltd.
Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancy
12/26
12/27
NCT03912064: A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Active, not recruiting
1
25
US
Ipilimumab, Yervoy, CD25hi Treg depleted DLI
Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia, Myelofibrosis
05/24
07/24
NCT06419634: Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recruiting
1
35
Canada, US
BMS-986497
Bristol-Myers Squibb
Acute Myeloid Leukemia, Myelodysplastic Syndrome
02/27
09/30
NCT05381181: Safety and Efficacy Evaluation of Next-generation CD19-UCART

Not yet recruiting
1
20
NA
CD19-UCART
Bioray Laboratories, The First Affiliated Hospital of Zhengzhou University
Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
05/24
05/26
NCT06346912: CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Recruiting
1
20
RoW
CD19-BAFF Targeted CAR T-cells, CD19-BAFF Targeted CAR T-cells injection
Zhejiang University, Shanghai YaKe Biotechnology Ltd.
Acute Lymphoblastic Leukemia,B-Cell, Non-hodgkin Lymphoma,B Cell
05/27
05/27
NCT03113643: SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Hourglass Jan 2021 - Mar 2021 : From trial for CD123 enriched AML
Hourglass Jul 2020 - Sep 2020 : Data from trial for 1L and relapsed/refractory AML or high-risk MDS
Recruiting
1
72
US
Azacitidine, Vidaza, SL-401, Venetoclax, Venclyxto, Venclexta
Dana-Farber Cancer Institute, Stemline Therapeutics, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm
05/25
05/26
NCT03843528: Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

Recruiting
1
15
US
Vorinostat, Azacitidine Injection
Johns Hopkins All Children's Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Juvenile Myelomonocytic Leukemia
07/24
10/24
ChiCTR2100054600: A-319 (a bispecific T cell engager) In Refractory/Relapse B-cell Acute Lymphoblastic Leukemia: a multicenter, open-label and dose-escalating phase I trial

Recruiting
1
54
 
Dosage of the study drug: week 1-4: 0.1 μg/kg A-319 ;Dosage of the study drug: week 1-2: 0.1 μg/kg A-319. Dosage of the study drug: week 3-4: 0.2 μg/kg A-319 ;Dosage of the study drug: week 1-2: 0.1 μg/kg A-319. Dosage of the study drug: week 3-4: 0.4 μg/kg A-319 ;Dosage of the study drug: week 1-2: 0.1 μg/kg A-319. Dosage of the study drug: week 3-4: 0.6 μg/kg A-319 ;Dosage of the study drug: week 1-2: 0.1 μg/kg A-319. Dosage of the study drug: week 3-4: 0.8 μg/kg A-319 ;Dosage of the study drug: week 1-2: 0.1 μg/kg A-319. Dosage of the study drug: week 3-4: 1.2 μg/kg A-319 ;Dosage of the study drug: week 1-2: 0.1 μg/kg A-319. Dosage of the study drug: week 3-4: 2.4 μg/kg A-319 ;the maximum tolerated dose (MTD) determined by the dose escalating phase of the trial, or the dose recommended by the phase II clinical trial
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine; Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Tianmaiyuanhe Biomedicine (Shanghai) Co., Ltd.
Acute B lymphoblastic leukemia
 
 
KQ-2002-XC001, NCT06445803: CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Recruiting
1
48
RoW
KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）
Rong Tao, Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
10/26
12/26
TG-1701-101, NCT03671590: Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Checkmark From a trial for CLL at EHA 2020
Jun 2020 - Jun 2020: From a trial for CLL at EHA 2020
Terminated
1
172
Europe, RoW
TG-1701, Umbralisib, TGR-1202, Ublituximab, TG-1101
TG Therapeutics, Inc.
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
05/24
05/24
NCT04732845: Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Recruiting
1
36
US
Fully human anti CD19 CAR-T Cell Dose, Fludarabine, Fludara, Cyclophosphamide, Cytoxan, Endoxan, Neosar, Procytox, Revimmune, Cycloblastin
Benjamin Tomlinson
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
06/24
12/24
NCT05088356: Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Recruiting
1
40
US
Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Beneflur, SH T 586, fludarabine monophosphate, Melphalan, Melphalanum, CliniMACS CD34 Reagent System, Tacrolimus, Prograf, Advagraf, fujimycin, Cyclophosphamide, alkylating agent, Plerixafor, Mozobil, AMD 3100, LM-3100, Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent, filgrastim XM02, Thiotepa, Tepandina, Mycophenolate Mofetil (MMF), CellCept, Ruxolitinib, Jakafi
Stanford University, Orca Biosystems, Inc.
Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
12/25
12/25
NCT05528887: Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Recruiting
1
10
RoW
Autologous CAR-T cells, Fludarabine, Fludara, Cyclophosphamide, Cytoxan
The Affiliated People's Hospital of Ningbo University, UTC Therapeutics Inc.
Relapsed/Refractory Hematological Malignancies, Lymphoma, Myeloma, Leukemia
06/24
06/26
NCT05379647: Natural Killer (NK) Cell Therapy for B-Cell Malignancies

Recruiting
1
24
RoW
QN-019a, Rituximab, Cyclophosphamid, Fludarabine, VP-16
Zhejiang University, Hangzhou Qihan Biotech Co.,Ltd.
B-cell Lymphoma, B-cell Acute Lymphoblastic Leukemia
06/24
12/24
NCT05400122: Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Recruiting
1
12
US
Vactosertib, TEW-7197, EW-7197, EW7197, Fludarabine Phosphate, Fludara, Cyclophosphamide, Cytoxan, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, IL-2, Proleukin, Natural Killer Cells
Jennifer Eva Selfridge
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma
12/25
06/26
NCT06398457: Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Not yet recruiting
1
8
NA
Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score, JH-DSA Semi-Quant Screen Score, JH-DSA Semi-Quant Response Score
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Janssen Research & Development, LLC
Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
06/26
12/26
NCT06376162: Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

Not yet recruiting
1
20
NA
Ziftomenib, Cytarabine, Fludarabine
LLS PedAL Initiative, LLC, Kura Oncology
Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia
08/27
08/27
BYON4413.001, NCT06359002: Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

Recruiting
1
100
Europe
BYON4413
Byondis B.V.
Relapsed / Refractory AML, Relapsed / Refractory MDS
12/26
03/27
CYNK001AML01, NCT04310592: Natural Killer Cell (CYNK-001) Infusions in Adults With AML

Recruiting
1
94
US
CYNK-001
Celularity Incorporated
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
06/24
12/24
NCT03844815: Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

Recruiting
1
26
US
Decitabine, Venetoclax
University of Chicago, AbbVie
Acute Myeloid Leukemia
06/24
06/25
NCT06291220: A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Recruiting
1
80
US, RoW
Obinutuzumab, ABBV-453
AbbVie
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
07/29
07/29
NCT06326021: Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

Not yet recruiting
1
27
RoW
autologous FL-33 CAR T therapy, prior-HSCT donor-derived FL-33 CAR T therapy
Beijing GoBroad Hospital
Refractory/Relapsed Acute Myeloid Leukaemia
06/26
12/26
NCT06326008: Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

Not yet recruiting
1
48
NA
Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy
Beijing GoBroad Hospital
B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
06/26
12/26
NCT06343376: Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recruiting
1
36
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Echocardiography, EC, EGFRt/19-28z/IL-12 CAR T-lymphocytes, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
Roswell Park Cancer Institute
Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
06/27
06/29
NCT06287944: 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Not yet recruiting
1
15
US
Actinium Ac 225-DOTA-Daratumumab, 225Ac-DOTA-Daratumumab, [225Ac]-DOTA-Daratumumab, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Daratumumab, Daratumumab Biosimilar HLX15, Daratumumab-fihj, Darzalex, HLX15, HuMax-CD38, JNJ-54767414, Echocardiography, EC, Fludarabine, Fluradosa, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Infusion, Hematopoietic Stem Cell Transplantation, HSCT, SCT, Stem Cell Transplant, stem cell transplantation, Stem Cell Transplantation, NOS, Indium In 111-DOTA-Daratumumab, 111In-DOTA-Daratumumab, [111In]-DOTA-Daratumumab, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, Single-Photon Emission Computed, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, ST, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Tacrolimus, FK 506, FK-506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius, Total Marrow and Lymphoid Irradiation, TMLI
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
02/27
02/27
NCT04190550: Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

Active, not recruiting
1
24
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Idarubicin Hydrochloride, Idamycin, Idamycin PFS, Idarubicin HCl, IMI-30, SC-33428, Zavedos, Navtemadlin, (3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid, AMG 232, AMG-232, KRT 232, KRT-232, KRT232, MDM2 Inhibitor KRT-232
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
06/25
06/25
NCT05445765: Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

Not yet recruiting
1
10
RoW
anti-CD33 CAR T cells
iCell Gene Therapeutics, iCar Bio Therapeutics
Relapsed and/or Refractory Acute Myeloid Leukemia, High Risk Hematologic Malignancies
06/24
06/24
NCT05212584: CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma

Recruiting
1
24
RoW
CD7CAR T cells
iCell Gene Therapeutics, iCar Bio Therapeutics
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma
06/24
06/24
NCR300-2002, NCT06441084: A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation

Not yet recruiting
1
15
NA
NCR300 injection
Nuwacell Biotechnologies Co., Ltd., Beijing Friendship Hospital
Acute Myeloid Leukemia
12/28
12/31
NCT06357182: Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

Recruiting
1
24
US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Echocardiography, EC, Iadademstat, ORY 1001, ORY-1001, RG 6016, RG6016, RO 7051790, RO7051790, trans-N1-((1R,2S)-2-Phenylcyclopropyl)-1,4-cyclohexanediamine, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Questionnaire Administration, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
OHSU Knight Cancer Institute, Oregon Health and Science University, Oryzon Genomics S.A.
Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia
03/26
05/26
T-allo10, NCT03198234: Use of in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders

Recruiting
1
30
US
T-allo10
Roncarolo, Maria Grazia, MD, National Cancer Institute (NCI)
AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Mixed Phenotype Acute Leukemia, NHL - Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, ALL
07/24
07/25
NCT02890329: Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Active, not recruiting
1
48
US
Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy
National Cancer Institute (NCI)
Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
07/24
07/24
NCT03772925: Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Active, not recruiting
1
30
US
Belinostat, Beleodaq, PXD 101, PXD101, Pevonedistat, MLN4924, Nedd8-Activating Enzyme Inhibitor MLN4924
National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
07/24
07/24
UCHMC 1812, NCT03904251: CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Checkmark From P1b trial in combination with Mylotarg for r/r AML at ASH 2020
Nov 2020 - Nov 2020: From P1b trial in combination with Mylotarg for r/r AML at ASH 2020
Terminated
1
13
US
Gemtuzumab Ozogamicin, Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676, Liposome-encapsulated Daunorubicin-Cytarabine, CPX-351, Cytarabine-Daunorubicin Liposome for Injection, Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos
Jonsson Comprehensive Cancer Center, Pfizer, Jazz Pharmaceuticals, University of California, Los Angeles
Acute Myelogenous Leukemia
10/23
10/23
CATCHAML, NCT04318678: CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia

Active, not recruiting
1
32
US
CD123-CAR T, CD123-CAR T cells, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Mesna, Rituximab, Rituxan
St. Jude Children's Research Hospital
AML/MDS, B-ALL, T-ALL, BPDCN
07/24
07/25
NCT05333705: Donor Immune Cell Therapy for Acute Myeloid Leukemia

Recruiting
1
15
RoW
infusion of natural killer cells
First Affiliated Hospital Xi'an Jiaotong University
Acute Myeloid Leukemia
07/24
09/24
NCT04964505: Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

Recruiting
1
25
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, Onureg, U-18496, Vidaza, Uproleselan, GMI-1271, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Brian Jonas, GlycoMimetics Incorporated, National Cancer Institute (NCI)
Acute Myeloid Leukemia
07/24
01/25
NCT05292898: A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Active, not recruiting
1
20
RoW
LCAR-AIO Cells
Institute of Hematology & Blood Diseases Hospital, China, Nanjing Legend Biotech Co.
Acute Lymphocytic Leukemia
07/24
07/26
NCT05233618: Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)

Recruiting
1
44
US
Tagraxofusp, SL-701, Elzonris
Karen Ballen, MD
Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
07/24
10/26
NCT06208735: CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Not yet recruiting
1
24
Canada
CLIC-2201, Autologous CD22 targeting CAR-T cells
British Columbia Cancer Agency
B-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma, B-cell Lymphoma
08/26
08/27
NCT04657224: A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Active, not recruiting
1
75
Europe, US, RoW
JNJ-64264681, JNJ-67856633
Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia
07/25
07/25
NCT06247787: A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Not yet recruiting
1
36
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Echocardiography, EC, Fludarabine, Fluradosa, Hydrocortisone Sodium Succinate, (11beta)-21-(3-Carboxy-1-oxopropyl)-11,17-dihydroxypregn-4-ene-3,20-dione, Monosodium Salt, A-Hydrocort, Buccalsone, Corlan, Cortisol Sodium Succinate, Cortop, Efcortelan, Emergent-EZ, Flebocortid, Hidroc Clora, Hycorace, Hydro-Adreson, Hydrocort, Hydrocortisone 21-Sodium Succinate, Hydrocortisone Na Succinate, Kinogen, Nordicort, Nositrol, Sinsurrene, Sodium hydrocortisone succinate, Solu-Cortef, Solu-Glyc, Imetelstat, GRN 163L, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, Leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Lumbar Puncture, LP, Spinal Tap, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039
Children's Oncology Group
Recurrent Acute Myeloid Leukemia, Recurrent Juvenile Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Juvenile Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
04/26
04/26
LAUREL, NCT05933070: A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML

Terminated
1
2
Europe
INKmune
Inmune Bio, Inc.
Cancer, MDS-EB, Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML
03/24
04/24
NCT05016947: Venetoclax Plus Inotuzumab for B-ALL

Recruiting
1
26
US
Venetoclax, Venclexta, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Maxidex, Inotuzumab Ozogamicin, Besponsa
Dana-Farber Cancer Institute, AbbVie
B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL
07/24
06/26
NCT05487495: Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma

Recruiting
1
18
RoW
CD5 CAR T (CT125B)
Beijing Boren Hospital
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
07/24
07/24
NCT05263271: Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Recruiting
1
58
RoW
Gentulizumab
GeneScience Pharmaceuticals Co., Ltd., Ruijin Hospital, Shanghai Tong Ren Hospital, First Affiliated Hospital of Zhejiang University
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
07/24
07/24
NCT04219163: Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

Recruiting
1
18
US
CLL-1.CAR T cells
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine
Acute Myeloid Leukemia
07/24
07/38
NCT04872478: Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

Recruiting
1
50
US
MRX-2843
Meryx, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
07/24
12/24
NCT05424822: A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Recruiting
1
220
Europe, US, RoW
JNJ-80948543
Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
07/24
11/26
NCT05703542: BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recruiting
1
24
US
BXCL701, Talabostat
Eric Stephen Winer, MD
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
07/24
07/25
NCT06158100: Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Not yet recruiting
1
25
US
Venetoclax, Venclexta, Venclyxto, Azacitidine, Vidaza, Azadine, Donor Lymphocyte Infusion
Antonio M Jimenez Jimenez, AbbVie
Acute Myeloid Leukemia
07/29
07/29
NCT06399640: Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Not yet recruiting
1
60
US
Eltanexor, KPT-8602, Venetoclax, Bone Marrow Aspiration and Biopsy, Biospecimen Collection
Vanderbilt-Ingram Cancer Center, Karyopharm Therapeutics Inc, National Cancer Institute (NCI)
Relapsed Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
12/26
12/27
NCT02483312: A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

Recruiting
1
9
Canada
IL-12
University Health Network, Toronto, Ozmosis Research Inc.
Acute Myeloid Leukemia
08/24
08/24
NCT03560882: A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

Active, not recruiting
1
50
US
Atorvastatin
Joaquina Baranda
Malignant Disease, Solid Tumor, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Cancer, Relapsed Hematologic Malignancy
10/22
08/25
NCT03766126: Lentivirally Redirected CD123 Autologous T Cells in AML

Recruiting
1
12
US
CART123 cells; cyclophosphamide; fludarabine, T Cells Containing Anti-CD123 Signaling Domains
University of Pennsylvania
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia, Refractory
08/24
12/33
NCT03927261: PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Recruiting
1
88
US
PRGN-3006 T Cells
Precigen, Inc
Acute Myeloid Leukemia, Myelodysplastic Syndromes
08/24
08/25
NCT03932643: ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

Active, not recruiting
1
20
US
ONC201
University of Nebraska
Acute Myeloid Leukemia, Myelodysplastic Syndromes
08/24
08/27
NCT04007029: Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Recruiting
1
24
US
Chimeric Antigen Receptor T-Cell Therapy, CAR T Infusion, CAR T Therapy, CAR T-cell therapy, Chimeric Antigen Receptor T-cell Infusion, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP (cyclophosphamide) monohydrate, CTX (cytoxan), CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP fludarabine: 2-Fluoroadenine 9-beta-D-Arabinofuranoside 5'-Monophosphate, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Tocilizumab, Actemra, Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer, MRA (myeloma receptor antibody), R-1569, RoActemra
Jonsson Comprehensive Cancer Center, Parker Institute for Cancer Immunotherapy
CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Small Lymphocytic Lymphoma
08/24
08/25
NCT04653493: CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Not yet recruiting
1
22
RoW
CD19 CAR engineered autologous T-cells, Cyclophosphamide, Fludarabine, Mesna
Sabz Biomedicals, Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran, Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Iran
Relapsed B Cell Acute Lymphoblastic Leukemia (ALL), Refractory B Cell Acute Lymphoblastic Leukemia (ALL)
08/24
08/24
NCT05024552: Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Recruiting
1
22
US
Gilteritinib, Xospata, Vyxeos, daunorubicin-cytarabine
H. Lee Moffitt Cancer Center and Research Institute, Jazz Pharmaceuticals
Acute Myeloid Leukemia With FLT3/ITD Mutation
08/24
08/25
NCT04771572: Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Recruiting
1
100
US
LP-118
Newave Pharmaceutical Inc
Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase
10/25
10/25
NCT04328714: Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

Suspended
1
45
US
Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Edwin Horwitz, Ossium Health, Inc.
Acute Leukemia, Myelodysplastic Syndromes
08/24
08/24
NCT04937166: A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

Recruiting
1
36
US
DSP107, Azacitidine, Vidaza, Venetoclax, Venclexta, Venclyxto
Kahr Medical
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
08/24
12/24
NCT05480501: Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Recruiting
1
9
RoW
IM19 CAR-T cells
Beijing Immunochina Medical Science & Technology Co., Ltd.
Leukemia
08/24
10/24
NCT04500587: Phase 1 First in Human Study of ZN-d5 as a Single Agent

Recruiting
1
115
Europe, RoW
ZN-d5, Study Drug
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Non Hodgkin Lymphoma
08/24
01/25
NCT05467202: Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML

Not yet recruiting
1
20
RoW
CLL1 CAR-T
Zhejiang University
AML
08/24
08/25
NCT05463640: Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML

Not yet recruiting
1
20
RoW
ADGRE2 CAR-T
Zhejiang University
AML
08/24
08/25
NCT05467254: Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML

Not yet recruiting
1
20
RoW
CLL1+CD33 CAR-T
Zhejiang University
AML
08/24
08/25
NCT05473221: Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML

Not yet recruiting
1
20
RoW
CD33 CAR-T
Zhejiang University
AML
08/24
08/25
NCT06447987: Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Recruiting
1
24
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T Cells, CD19R(EQ)28zeta/EGFRt+ Naive and Memory T Cells, CD19R(EQ)28zetaEGFRt+ Tn/mem Cells, Cetuximab, C225, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Echocardiography, EC, Fludarabine, Fluradosa, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
08/25
08/25
OMNIVERSE, NCT04887857: A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

Completed
1
6
US, RoW
CC-486, ONUREG®, oral azacitidine, Venetoclax, VENCLEXTA®, VENCLYXTO®
Celgene, AbbVie
Leukemia, Myeloid, Acute
01/24
01/24
QLF32101-101, NCT05703204: A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Not yet recruiting
1
122
RoW
QLF32101
Qilu Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia and Myelodysplastic Syndrome
08/24
12/24
NCT04709458: Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

Not yet recruiting
1
10
Europe, RoW
TBX-2400
Taiga Biotechnologies, Inc.
Myelofibrosis, Acute Myelogenous Leukemia
08/24
10/24
NCT04240704 / 2019-002666-12: Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

Active, not recruiting
1
25
Europe, Japan, RoW
JBH492
Novartis Pharmaceuticals
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
09/24
09/24
NCT04174586: Cord Blood Microtransplantation for Treatment of Acute Myeloid Leukemia

Recruiting
1
20
RoW
microtransplantation
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Safety Issues, Efficiency
08/24
08/24
NCT05105867: CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

Recruiting
1
15
RoW
Anti-CD19 Universal CAR-T Cells injection
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Gracell Biotechnology Shanghai Co., Ltd., Kunming Hope of Health Hospital
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B-cell Non-hodgkin Lymphoma
08/24
11/24
NCT05651178: Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

Recruiting
1
20
RoW
Human CD19-CD22 Targeted T Cells Injection, CD19-CD22 CAR-T
Hrain Biotechnology Co., Ltd., Second Affiliated Hospital of Nanchang University
Central Nervous System Lymphoma
08/24
08/25
NCT05495035: Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

Recruiting
1
22
RoW
Olverembatinib, APG-2575, Dexamethasone
Institute of Hematology & Blood Diseases Hospital
Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia
08/24
12/24
NCT06440135: Ziftomenib Maintenance Post Allo-HCT

Not yet recruiting
1
22
US
Ziftomenib, KO-539
Massachusetts General Hospital
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, NPM1 Mutation, KMT2A Rearrangement
09/26
09/27
Encore-MDS, NCT02841540: A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

Terminated
1
127
Europe, US, RoW
H3B-8800 (RVT-2001)
Hemavant Sciences GmbH
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
02/24
02/24
NCT04072458: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Recruiting
1
30
US
L-Bcl-2 antisense oligonucleotide, BP1002
Bio-Path Holdings, Inc.
Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Marginal Zone Lymphoma, Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, DLBCL
09/24
01/26
2087GCCC, NCT04666649: Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Active, not recruiting
1
27
US
Venetoclax and pegcrisantaspase
University of Maryland, Baltimore
Relapsed or Refractory Acute Myeloid Leukemia
09/24
09/25
KNAN2001, NCT04716452: Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Not yet recruiting
1
18
US
Ceramide NanoLiposome (Ceraxa), Ceramide NanoLiposome
Keystone Nano, Inc, University of Virginia, Milton S. Hershey Medical Center
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory
09/24
12/24
NCT06313437: Revumenib in Combination With 7+3 + Midostaurin in AML

Not yet recruiting
1
22
US
Revumenib, SNDX-5613, Trans N-ethyl-2-((4-(7-((4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2- yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide, Midostaurin, Rydapt, Cytarabine, cytosine arabinoside (ara-C), Daunorubicin, Daunomycin
Maximilian Stahl, MD, Syndax Pharmaceuticals
Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia
03/26
03/27
NCT02390635: PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Active, not recruiting
1
55
US
Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, computerized tomography, CT, CT SCAN, tomography, Diffusion Weighted Imaging, Diffusion Weighted MRI, Diffusion-Weighted Magnetic Resonance Imaging, Diffusion-Weighted MR Imaging, Diffusion-Weighted MRI, DW-MRI, DWI, DWI MRI, DWI-MRI, MR Diffusion-Weighted Imaging, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Gadolinium, Gd, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Three-Dimensional Spoiled Gradient MRI, 3-Dimensional Fast Spoiled Gradient, 3D Fast Spoiled Gradient Recalled MRI, 3D FSPGR, 3DFSPGR, FSPGR, FSPGR MRI, SPGR, SPGR MRI, Three-Dimensional Spoiled Gradient-Echo MR
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA
09/24
09/24
NCT06195891: Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

Recruiting
1
33
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Dual-Energy Computed Tomography, DECT, Echocardiography, EC, Fludarabine, Fluradosa, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Partially Engineered T-regulatory Cell Donor Graft TRGFT-201, Orca-T, Partially Engineered and Enriched Treg Donor Graft TRGFT-201, T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, TregGraft, TRGFT 201, TRGFT-201, TRGFT201, Tacrolimus, FK 506, FK-506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Total Marrow and Lymphoid Irradiation, TMLI
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
06/27
06/27
NCT04629729: FT819 in Subjects With B-cell Malignancies

Recruiting
1
396
US
FT819, Cyclophosphamide, Fludarabine, Fludara, IL-2, Interleukin-2, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
09/24
09/39
NCT05651191: To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL

Recruiting
1
9
RoW
Human CD19 Targeted DASH CAR-T Cells Injection, CD19 DASH CAR-T
Hrain Biotechnology Co., Ltd., Second Affiliated Hospital of Nanchang University
B-cell Acute Lymphoblastic Leukemia
09/24
09/25
XmAb13676-01, NCT02924402: Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Checkmark Presentation of data from trial for NHL at ASH 2022
Nov 2022 - Nov 2022: Presentation of data from trial for NHL at ASH 2022
Checkmark From trial for NHL and CLL at ASH 2021
Dec 2021 - Dec 2021: From trial for NHL and CLL at ASH 2021
Checkmark From trial in hematologic malignancies at ASH 2019
More
Active, not recruiting
1
270
Europe, US, RoW
XmAb13676
Xencor, Inc., ICON Clinical Research
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
10/24
01/25
NCT03441048: Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Checkmark 1-Year and 2-Year overall survival data from a trial for R/R AML at ASH 2022
Nov 2022 - Nov 2022: 1-Year and 2-Year overall survival data from a trial for R/R AML at ASH 2022
Hourglass Jun 2021 - Dec 2021 : Completion of fourth cohort of P1 trial in combination with CLAG-M for r/r AML
Checkmark Data from trial in combination with CLAG-M for r/r AML
Dec 2021 - Dec 2021: Data from trial in combination with CLAG-M for r/r AML
More
Completed
1
26
US
Lintuzumab-Ac-225 (Dose 1: 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab), HuM195-Ac225, Actimab-A, Cladribine, Leustatin, Mavenclad, Cytarabine, Cytosar-U, Depocyt, cytosine arabinoside (ara-C), Mitoxantrone, Mitozantrone, Novantrone, G-CSF, colony-stimulating factor 3 (CSF 3), Lintuzumab-Ac-225 (Dose 2: 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab), Lintuzumab-Ac-225 (Dose 3: 0.75 μCi/kg with 4.7μg/kg lintuzumab), Lintuzumab-Ac-225 (Dose 4: 1.00 μCi/kg with 6.4 μg/kg lintuzumab), Lintuzumab-Ac-225 (Dose 5: 1.25 μCi/kg with 8.0 μg/kg lintuzumab), Lintuzumab-Ac-225 (Recommended Phase 2 Dose)
Medical College of Wisconsin
Acute Myeloid Leukemia
05/24
05/24
ODYSSEY, NCT05601726: First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients

Active, not recruiting
1
7
Europe
ABD-3001, DIMATE
Advanced BioDesign
Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes
10/24
12/24
NCT04207190: Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting
1
24
US
Gemtuzumab Ozogamicin, Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Talazoparib, BMN 673, BMN-673, Talazoparib Tosylate, Talzenna
Roswell Park Cancer Institute, Pfizer
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
04/25
04/25
NCT06397027: A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

Not yet recruiting
1
22
US
Ziftomenib, Venetoclax, ABT-199, GDC-0199, Azacitidine, 5-azacytidine,, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, Azacytidine, NSC-102816
M.D. Anderson Cancer Center, Kura Oncology, Inc.
Refractory Acute Leukemia, Pediatric Relapsed
12/28
12/30
NCT06401603: A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Not yet recruiting
1
30
US
Decitabine, Dacogen, Listaftoclax, Olverembatinib
M.D. Anderson Cancer Center, Ascentage Pharma Group Inc.
Advanced Chronic Myeloid Leukemia, Philadelphia Chromosome-Positive Acute Myeloid Leukemia
01/27
01/29
NCT04606433: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Recruiting
1
41
RoW
GNC-038
Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
11/24
11/24
ILDA, NCT04886206: Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
1
12
Europe
DLI
Nantes University Hospital
Acute Myeloid Leukemia (AML)
11/24
11/24
NCT05775406: Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

Recruiting
1
70
US
KT-253
Kymera Therapeutics, Inc.
Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors
11/24
11/25
NCT06171152: Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

Not yet recruiting
1
30
NA
Liraglutide Pen Injector [Saxenda], Saxenda, Victoza, Medication Diary
University of Chicago
Multiple Sclerosis, Long COVID, Long Covid19, Obese, Obesity, Obesity, Morbid, Acute Leukemia in Remission
06/26
10/26
NCT03422731: Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

Recruiting
1
74
US
Biospecimen Collection, Dual-Energy Computed Tomography, DECT, Fluorothymidine F-18, 18F-FLT, 3''-Deoxy-3''-(18F) Fluorothymidine, 3''-deoxy-3''-[18F]fluorothymidine, ALOVUDINE F-18, Fluorothymidine F 18, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
11/24
11/24
 

Download Options